Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Eton Pharmaceuticals Inc. (NASDAQ:ETON) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Eton Pharmaceuticals Inc.||6||0.00||10.01M||-2.36||0.00|
Table 1 highlights CRISPR Therapeutics AG and Eton Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.
Table 2 demonstrates the net margins, return on equity and return on assets of CRISPR Therapeutics AG and Eton Pharmaceuticals Inc.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,235,636.97%||-2.6%||-2%|
|Eton Pharmaceuticals Inc.||166,279,069.77%||-223.5%||-200.7%|
The Current Ratio of CRISPR Therapeutics AG is 8.3 while its Quick Ratio stands at 8.3. The Current Ratio of rival Eton Pharmaceuticals Inc. is 10.9 and its Quick Ratio is has 10.9. Eton Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than CRISPR Therapeutics AG.
The next table highlights the given recommendations and ratings for CRISPR Therapeutics AG and Eton Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Eton Pharmaceuticals Inc.||0||0||2||3.00|
CRISPR Therapeutics AG’s upside potential currently stands at 8.55% and an $72 consensus target price. Eton Pharmaceuticals Inc. on the other hand boasts of a $17.25 consensus target price and a 173.81% potential upside. The information presented earlier suggests that Eton Pharmaceuticals Inc. looks more robust than CRISPR Therapeutics AG as far as analyst belief.
Insider & Institutional Ownership
CRISPR Therapeutics AG and Eton Pharmaceuticals Inc. has shares owned by institutional investors as follows: 46.8% and 12.8%. CRISPR Therapeutics AG’s share owned by insiders are 0.4%. Competitively, insiders own roughly 6.2% of Eton Pharmaceuticals Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Eton Pharmaceuticals Inc.||-6.72%||-0.33%||4.92%||-25.09%||-2.93%||-2.45%|
For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Eton Pharmaceuticals Inc. has -2.45% weaker performance.
On 6 of the 10 factors CRISPR Therapeutics AG beats Eton Pharmaceuticals Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.